Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about VCEL, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Carticel (autologous cultured chondrocyte)… | Articular Cartilage | Phase 4 · NCT00158613 | Completed |
| autologous cultured chondrocytes on porcine… | Chondral Defect | Phase 3 · NCT06915233 | Recruiting |
| Ixmyelocel-T | Critical Limb Ischemia | Phase 3 · NCT01483898 | Completed |
| Autologous Cultured Chondrocytes | Chondral Defect | Phase 3 · NCT03588975 | Recruiting |
| Bone Repair Cells (BRCs) | Single Level Posterolateral Spinal Fusion | Phase 1/2 · NCT00797550 | Terminated |
| Cultured Bone Marrow Tissue | Fracture, Ununited | Phase 1/2 · NCT00424567 | Terminated |
| Tissue Repair Cells (TRC) | Alveolar Bone Loss | Phase 1/2 · NCT00755911 | Completed |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
VCEL holds $235.6M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.
Dilution pressure: 0 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when VCEL files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Vanguard Capital Management | Institution (13G, 5%+) | 2,603,128 | 5.10% | 2026-03-31 |
| Dominick Colangelo President and CEO, Director · +237,250 options |
Insider | 312,446 | 0.61% | 2026-02-24 |
| Jonathan Mark Hopper Chief Medical Officer · +71,757 options |
Insider | 75,753 | 0.15% | 2026-06-26 |
| Alan L Rubino Director · +11,200 options |
Insider | 64,194 | 0.13% | 2026-04-29 |
| Heidi Hagen Director · +11,200 options |
Insider | 35,050 | 0.07% | 2026-04-29 |
| Robert L Md Zerbe Director · +11,200 options |
Insider | 32,995 | 0.06% | 2026-11-09 |
| Paul K Wotton Director · +11,200 options |
Insider | 18,802 | 0.04% | 2026-05-11 |
| Kevin F Mclaughlin Director · +11,200 options |
Insider | 18,300 | 0.04% | 2026-11-10 |
| Michael Halpin Chief Operating Officer · +89,250 options |
Insider | 16,394 | 0.03% | 2026-08-03 |
| Joseph Anthony Jr Mara Chief Financial Officer · +251,011 options |
Insider | 16,186 | 0.03% | 2026-11-09 |
| Lisa Wright Director · +11,200 options |
Insider | 15,851 | 0.03% | 2026-04-29 |
| Sean C. Flynn Chief Legal Officer · +81,000 options |
Insider | 1,990 | 0.00% | 2026-11-05 |
Share count 51,029,770 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for VCEL and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →